Qiagen N.V. (NYSE:QGEN) Given Average Recommendation of “Hold” by Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have been assigned a consensus recommendation of “Hold” from the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $55.1988.

Several equities research analysts have recently commented on QGEN shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $59.00 target price on shares of Qiagen in a research report on Thursday, February 5th. Citigroup reduced their price target on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. JPMorgan Chase & Co. increased their price target on shares of Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Stifel Nicolaus set a $50.00 price objective on Qiagen and gave the company a “hold” rating in a research report on Friday, February 6th. Finally, Barclays set a $58.00 target price on Qiagen and gave the stock an “overweight” rating in a report on Friday, February 6th.

Hedge Funds Weigh In On Qiagen

A number of institutional investors have recently added to or reduced their stakes in QGEN. Danske Bank A S bought a new stake in shares of Qiagen during the 3rd quarter valued at $36,000. Smartleaf Asset Management LLC increased its stake in shares of Qiagen by 1,383.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after acquiring an additional 830 shares in the last quarter. Manchester Capital Management LLC bought a new position in shares of Qiagen in the 4th quarter worth about $42,000. MAI Capital Management lifted its position in Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after acquiring an additional 889 shares during the period. Finally, Allworth Financial LP boosted its stake in Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after acquiring an additional 796 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

QGEN opened at $43.36 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. Qiagen has a 52-week low of $40.14 and a 52-week high of $57.81. The stock has a market capitalization of $9.16 billion, a PE ratio of 21.50, a price-to-earnings-growth ratio of 2.17 and a beta of 0.70. The stock’s 50 day moving average price is $49.80 and its 200-day moving average price is $49.11.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The company had revenue of $540.42 million during the quarter, compared to analyst estimates of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm’s revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 earnings per share. On average, equities research analysts predict that Qiagen will post 2.26 EPS for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.